Fig. 1: This figure shows the flow of patients in the study and responses acheived at different time points in the study.
From: Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
A Consort diagram. 1276 patients were treated with upfront Bortezomib from Feb 2010 to Aug 2019. 82/1276 (6.4%) had dFLC < 20 mg/l and are excluded from the analysis. There are 1194, 1133, 1038, and 948 patients in the ITT, 1-month, 3-month and 6-month landmark cohorts. B Shows the haematologic responses 1 month, 3 months and 6 months. In the ITT cohort 137 (11.5%), 270 (22.6%), 252 (21.1%) and 413 (34.6%) patients had a CR, VGPR, PR and NR at 1 month, respectively. There was a progressive improvement in the proportion of patients with a deeper response (≥ VGPR) from 34.1% at one month to 57.1% and 65% at 3 and 6 months, respectively.
